DEF 14A: Zimmer Biomet Holdings, Inc. Outlines Key Governance and Compensation Strategies in Proxy Statement

Zimmer Biomet's proxy statement details the company's corporate governance framework, executive compensation practices, and proposals for the upcoming annual shareholder meeting.

Summary

• Zimmer Biomet's proxy statement outlines key aspects of its corporate governance, including board composition, risk oversight, and executive succession planning.
• The document highlights the company's commitment to diversity, equity, and inclusion, as well as shareholder engagement on ESG priorities.
• Shareholders are being asked to vote on the election of directors, ratification of the appointment of PricewaterhouseCoopers LLP, approval of executive compensation, and approval of the amended Employee Stock Purchase Plan.
• The Board recommends voting in favor of all proposals.
• The proxy statement details the compensation of the named executive officers (NEOs) for 2023, including base salary, cash incentives, and equity incentives.
• The document discusses the company's response to the 2023 Say on Pay vote and shareholder feedback, including commitments to enhance disclosure and align executive compensation with shareholder interests.
• The proxy statement also includes information on the company's equity compensation plan, including the number of securities to be issued and the weighted-average exercise price.
• The company is asking shareholders to approve an increase of 10,000,000 shares in the number of shares reserved under the ESPP.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for the company, highlighting its commitment to innovation, shareholder value, and ethical business practices. The Board's recommendations and the company's response to shareholder feedback further contribute to a positive sentiment.

Positives

• The company has a diverse Board with an effective mix of skills, experiences and perspectives.
• The company has a robust Board and executive succession planning and risk oversight process.
• The company has a rigorous stock ownership guidelines for directors and executives.
• The company has a robust Code of Business Conduct and Ethics applicable to directors, officers and employees.
• The company has a clawback of incentive compensation policy.
• The company requires a double trigger for change in control benefits.
• The company requires a non-competition agreement for equity award eligibility.

Risks

• The document mentions risks, uncertainties and changes in circumstances that could cause actual results to differ materially from forward-looking statements, as detailed in the company's Annual Report on Form 10-K.
• The document mentions general commercial risks in the musculoskeletal healthcare industry, such as competition, pricing pressures and the reimbursement landscape; risks associated with our strategic plan and annual operating plan; risks related to our capital structure; and risks pertaining to mergers, acquisitions, divestitures and other complex transactions.

Future Outlook

The company remains committed to delivering on its nearand long-term corporate strategy and on the innovation and execution necessary to achieve it.

Management Comments

• I am very proud of the meaningful progress and growth driven by the Zimmer Biomet team in 2023. It was a year of significant achievements, all aimed toward serving our customers and creating shareholder value, and ultimately guided by our Mission to alleviate pain and improve the quality of life for people around the world Ivan Tornos, President and Chief Executive Officer
• We remain committed to serving your interests in 2024 and beyond, and are confident in the future of Zimmer Biomet Christopher Begley, Chairman of the Board

Industry Context

The announcement reflects broader trends in the medical device industry, including a focus on innovation, global expansion, and shareholder value creation.

Comparison to Industry Standards

• The company's executive compensation program is designed to be competitive with a peer group of publicly traded companies, including Agilent Technologies, Inc., Align Technology, Inc., Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, DexCom, Inc., Edwards Lifesciences Corporation, Hologic, Inc., Intuitive Surgical, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Stryker Corporation, Teleflex Incorporated, and The Cooper Companies, Inc.
• The company's compensation practices are aligned with those of other large healthcare equipment and services companies, life sciences services companies and companies with whom we compete for business and for executive talent.

Management Changes

Related Party Transactions

• In February 2018, we entered into an aircraft time sharing agreement with Bryan Hanson, our former Chairman, President and Chief Executive Officer.
• Al Hanson, Jr., a Regional Sales Director in Restorative Therapies for our Sports Medicine business, is the brother of Bryan Hanson, our former Chairman, President and Chief Executive Officer.

Stakeholder Impact

• The company's actions are aimed at serving its customers, creating shareholder value, and improving the quality of life for people around the world.
• The company is committed to maintaining the highest standards of business conduct and corporate governance, which it believes are essential to running its business efficiently, serving shareholders well and maintaining its integrity in the marketplace.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting of shareholders on May 10, 2024.
• The company expects to release its next Sustainability Report this spring.

Key Dates

Keywords

executive compensation, corporate governance, board of directors, shareholder engagement, proxy statement, risk oversight, PricewaterhouseCoopers, employee stock purchase plan, Say on Pay, Zimmer Biomet